Levofloxacin derivatives of heptamethrin and their preparation methods and applications

By constructing heptamethrin-based levofloxacin derivative MHI-LFX@Pt(IV)@Lip nanoparticles, the AMPK pathway was activated to synergistically downregulate CD47 and PD-L1, solving the tolerance problem of platinum-based drugs in chemotherapy-immunotherapy and achieving the effect of highly efficient inhibition of tumor growth and reduction of systemic toxicity at low doses.

CN123106643APending Publication Date: 2026-11-17WENZHOU MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611016987.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-09
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing platinum-based anticancer drugs have problems with systemic toxicity and insufficient tumor selectivity during treatment, and they are difficult to effectively regulate the expression of CD47 and PD-L1, leading to chemotherapy-immunotherapy tolerance.

Method used

We constructed heptamethasone-based levofloxacin derivative MHI-LFX@Pt(IV)@Lip nanoparticles, which enhanced the efficacy of chemotherapy-immunotherapy by activating the AMPK pathway and synergistically downregulating CD47 and PD-L1 expression.

Benefits of technology

At low doses, it significantly inhibits local and distant tumor growth, reduces systemic toxicity, and improves the efficacy of chemotherapy-immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106643A_ABST
    Figure CN123106643A_ABST
Patent Text Reader

Abstract

This invention relates to the field of nanomedicine delivery systems. To address the problem of innate and adaptive immune tolerance caused by elevated PD-L1 and CD47 expression after platinum-based anticancer drug treatment, this invention proposes a heptamethrin (MHI)-based levofloxacin (LFX) derivative, its preparation method, and its application. By first synthesizing heptamethrin dye and then chemically synthesizing the heptamethrin-based levofloxacin derivative, since MHI-LFX can simultaneously inhibit CD47 and PD-L1, this invention constructs MHI-LFX@Pt(IV)@Lip nanoparticles, which significantly inhibit the growth of local and distant tumors by stimulating innate and adaptive immune responses.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of nanomedicine delivery systems, specifically to heptamethrin-based levofloxacin derivatives, their preparation methods, and applications. Background Technology

[0002] Platinum (Pt)-based anticancer drugs have been widely used clinically to treat various solid tumors, including breast cancer, bladder cancer, ovarian cancer, and lung cancer. Platinum-based anticancer drugs not only induce tumor cell apoptosis by damaging cellular DNA and inhibiting DNA replication, but also trigger immune activation by inducing immunogenic cell death and activating the cGAS-STING pathway. However, some unavoidable side effects, such as high systemic toxicity and lack of tumor selectivity, limit their application. Furthermore, in addition to inducing adaptive immune tolerance by enhancing programmed death-ligand 1 (PD-L1) expression, platinum-based drugs also promote macrophage-mediated innate immune escape by increasing the expression of the immune checkpoint protein CD47 on tumor cell membranes—a phenomenon often overlooked. To address these issues, researchers have developed various platinum-based nanomaterials, such as platinum nanoclusters and nanoparticles loaded with Pt(IV) prodrugs. However, few studies have been able to simultaneously regulate CD47 and PD-L1 to enhance the efficacy of platinum-based chemotherapy-immunotherapy. Therefore, it remains essential to improve the efficacy of platinum-based anticancer drugs by effectively and synergistically downregulating CD47 and PD-L1.

[0003] To address this, bispecific antibodies targeting CD47 / PD-L1, such as IMM2520, PF-07257876, and BAT7104, have been developed and extensively studied to simultaneously block PD-L1 and CD47 in tumor cells. However, these strategies often suffer from immunotoxicity issues, such as erythrocyte agglutination and hemolysis, making them less than ideal methods for the synergistic regulation of PD-L1 and CD47. In recent years, nanoparticle-mediated tumor metabolic regulation (such as inhibition of oxidative phosphorylation (OXPHOS) or glycolysis) has been shown to inhibit PD-L1 expression by activating phosphorylation of adenosine monophosphate-activated protein kinase (AMPK). However, salicylic acid, AICAR, and 4-O-methylantimycin, by activating AMPK, can also inhibit c-MYC by reducing c-MYC mRNA levels and promoting its instability and degradation. Given that c-MYC has been shown to enhance CD47 expression in tumor cells, activation of AMPK (AMP-activated protein kinase) may simultaneously inhibit PD-L1 and CD47, thereby enhancing the efficacy of platinum-based chemotherapy-immunotherapy.

[0004] Currently, fluoroquinolones (such as levofloxacin (LFX), moxifloxacin, and lomefloxacin) are widely used clinically as antibacterial agents. Studies have shown that fluoroquinolones can also inhibit tumor mitochondrial oxidative phosphorylation (OXPHOS) by suppressing the function of the mitochondrial electron transport chain complex, thereby reducing adenosine triphosphate (ATP) production. With an increase in the adenosine diphosphate (ADP) / ATP ratio, the AMPK pathway may be activated, thereby simultaneously inhibiting the expression of PD-L1 and CD47. Therefore, some fluoroquinolones may be able to enhance the efficacy of platinum-based chemotherapy-immunotherapy. Summary of the Invention

[0005] To address the issue of innate and adaptive immune tolerance caused by elevated PD-L1 and CD47 expression after platinum-based anticancer drug therapy, this invention proposes a heptamethrin (MHI)-based levofloxacin (LFX) derivative, its preparation method, and its applications. Since MHI-LFX can simultaneously inhibit CD47 and PD-L1, this invention constructs MHI-LFX@Pt(IV)@Lip nanoparticles, which significantly inhibit the growth of local and distant (bystander effect) tumors by stimulating innate and adaptive immune responses.

[0006] The technical solution of the present invention is as follows: a heptamethrin-based levofloxacin derivative, the structural schematic diagram of which is shown in (I). (I).

[0007] The preparation method of the above-mentioned heptamethrin-based levofloxacin derivatives includes the following steps: (1) First, synthesize heptamethrin dye (MHI): The chemical synthesis steps of heptamethrin cyanine dye (MHI) are as follows: At room temperature, sodium acetate, N-[(3-(anilinemethylene)-2-chloro-1-cyclohexene-1-methylene]aniline monohydrochloride, n-ethyl-2,3,3-trimethylindole iodide and 1-(5-carboxyl)-2,3,3-trimethylindole bromide are first added to anhydrous ethanol. Then, the above reactants are mixed in an oil bath and heated under reflux to obtain heptamethrin cyanine dye (MHI). Preferably, the molar ratio of sodium acetate, N-[(3-(anilinemethylene)-2-chloro-1-cyclohexene-1-methylene]aniline monohydrochloride, n-ethyl-2,3,3-trimethylindole iodide, and 1-(5-carboxyl)-2,3,3-trimethylindole bromide is 1:0.8-1.2:0.8-1.2:0.8-1.2. Preferably, the amount of anhydrous ethanol used is the amount required to dissolve the solute.

[0008] (2) Re-chemical synthesis of heptamethrin-based levofloxacin derivatives (2.1) Synthesis of LFX-NH2: Levofloxacin (LFX) was dissolved in a mixed organic solution of anhydrous dichloroethane and methanol, N-Boc-propanediamine was added, a catalyst was added, and the mixture was reacted at room temperature and then purified to obtain LFX-NH2. 2- Boc, after purification, was desalted with trifluoroacetic acid and NaOH to produce LFX-NH2; Preferably, the molar ratio of N-Boc-propanediamine, catalyst, and levofloxacin is 1.5-2:0.8-1.2:1.

[0009] (2.2) Synthesis of heptamethrin-based levofloxacin derivatives: LFX-NH2 was dissolved in a mixed organic solution of anhydrous dichloroethane and methanol, MHI and catalyst were added, and the reaction was carried out at room temperature. After removing the organic solvent, the product heptamethrin-based levofloxacin derivatives was obtained by purification.

[0010] Preferably, the molar ratio of MHI, catalyst and LFX-NH2 is 0.1-1:0.1-1:1.

[0011] Preferably, the catalyst used in the above reaction is selected from 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (DMTMM).

[0012] Preferably, the volume ratio of anhydrous dichloroethane to methanol in the above-mentioned mixed organic solution of anhydrous dichloroethane and methanol is 1:0.5-1.5, and the amount used is the amount required to dissolve the solute.

[0013] Preferably, the above purification method involves drying the reaction system using a rotary evaporator and then purifying it using silica gel column chromatography.

[0014] Preferably, the reaction time at room temperature is greater than 24 hours.

[0015] To promote the specific delivery of levofloxacin (LFX) to the mitochondria of tumor cells, this invention functionalizes levofloxacin (LFX) with the mitochondrial-targeting dye MHI, constructing a levofloxacin derivative MHI-LFX. By regulating the AMPK / c-MYC axis, the synergistic downregulation of PD-L1 and CD47 can be achieved more efficiently. The MHI group successfully targets and delivers levofloxacin (LFX) to the mitochondria, thereby enhancing its pharmacological activity.

[0016] The reaction formula is shown below:

[0017] The application of the heptamethrin-based levofloxacin derivative in the construction of MHI-LFX@Pt(IV)@Lip nanoparticles enables the targeted delivery of antibacterial fluoroquinolone drugs to mitochondria via nanoparticle-mediated delivery, thereby overcoming platinum-mediated chemotherapy-immunotherapy resistance. The nanostructure of MHI-LFX@Pt(IV)@Lip is shown in (II): (II).

[0018] MHI-LFX and Pt(IV) prodrug were co-loaded into clinically available liposomal nanoparticles. Following intravenous administration, MHI-LFX@Pt(IV)@Lip effectively targeted and accumulated at tumor sites, thereby reducing the systemic toxicity of cisplatin. In a glutathione (GSH)-rich tumor microenvironment, the Pt(IV) prodrug was reduced to release cisplatin, subsequently inducing tumor cell apoptosis. Furthermore, MHI-LFX@Pt(IV)@Lip significantly inhibited the growth of both local and distant (bystander effect) tumors by stimulating innate and adaptive immune responses.

[0019] The preparation method of the MHI-LFX@Pt(IV)@Lip nanoparticles includes the following steps: (1) The chemical synthesis process of the Pt(IV) tetravalent platinum prodrug is shown below:

[0020] (1.1) Weigh Pt(II), add excess hydrogen peroxide solution, react under light-protected conditions, centrifuge, filter, extract and purify to obtain Pt(IV)-OH; then add DMSO solution, stir and dissolve at room temperature, add succinic anhydride, after the reaction at room temperature is completed, remove the reaction solution, add methanol and diethyl ether in sequence, and purify repeatedly to obtain Pt(IV)-COOH; Preferably, the molar ratio of Pt(II) to hydrogen peroxide solution is 1:10-15, and more preferably, the mass concentration of hydrogen peroxide solution is 30%.

[0021] Preferably, the molar ratio of succinic anhydride to Pt(IV)-OH is 1.5-2.5:1.

[0022] Preferably, the reaction solution is removed by vacuum rotary evaporation, and methanol and diethyl ether are added sequentially to precipitate the product.

[0023] (1.2) Weigh Pt(IV)-COOH, add DMSO solution, and then add catalysts 1-ethyl-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide in sequence. After the reaction solution is reacted in the dark at room temperature, DSPE-NH2 (distearate phosphatidylethanolamine-amino) is added to the reaction solution. After the reaction is completed, the catalyst is removed and further precipitation is carried out to obtain the product Pt(IV) tetravalent platinum prodrug.

[0024] Preferably, the molar ratio of Pt(IV)-COOH, catalyst 1-ethyl-(3-dimethylaminopropyl)carbodiimide, N-hydroxysuccinimide, and DSPE-NH2 is 1:1-2:1-2:1-2.

[0025] Preferably, the catalyst EDC and NHS are removed by two-phase extraction of the organic phase and aqueous phase.

[0026] Preferably, the amount of DMSO solution used is the amount used to dissolve the solute.

[0027] Preferably, the above reactions all take longer than 24 hours.

[0028] (2) Construction of MHI-LFX@Pt(IV)@Lip nanoparticles A mixture of HSPC (hydrogenated soybean phosphatidylcholine), cholesterol, DSPE-PEG2000, and Pt(IV) was dissolved in chloroform to form a lipid film. Distilled water and MHI-LFX were then added to the film, and the mixture was sonicated to obtain a liposome emulsion. The resulting vesicles were homogenized. Finally, the solution was subjected to pressure ultrafiltration until a colorless filtrate was obtained, which was MHI-LFX@Pt(IV)@Lip nanoparticles.

[0029] As a preferred option, the mass ratio of HSPC, cholesterol, DSPE-PEG2000, and Pt(IV) is 1-2:0.5-1.5:1-2:1.

[0030] Preferably, the solution is placed in a round-bottom flask and a rotary evaporator is used to form a dry lipid film.

[0031] Preferably, the dosage of distilled water, MHI-LFX and Pt(IV) is 0.2-0.6 mL: 0.05-0.2 mg: 1 mg.

[0032] Preferably, the obtained vesicles are manually extruded N times through a 200 nm polycarbonate membrane for homogenization.

[0033] Preferably, the solution is placed in a stirred ultrafiltration cup with a molecular weight cutoff of 30 kDa and subjected to pressure ultrafiltration until a colorless filtrate is obtained.

[0034] This invention constructs MHI-LFX@Pt(IV)@Lip, which co-loads the cisplatin prodrug Pt(IV) and MHI-LFX into clinically available liposomal nanoparticles. The nanoparticles can avoid the immune tolerance often induced by cisplatin. Both in vitro and in vivo, the MHI-LFX@Pt(IV)@Lip nanoparticles can re-encapsulate fluoroquinolone drugs to overcome platinum-based chemotherapy-immunotherapy tolerance. Therefore, the MHI-LFX@Pt(IV)@Lip nanoparticles of this invention serve as a liposomal dual-drug loaded nanoparticle drug delivery system.

[0035] Compared with the prior art, the beneficial effects of the present invention are: (1) The present invention synthesizes a heptamethrin-based levofloxacin derivative (MHI-LFX), which can more effectively achieve synergistic downregulation of PD-L1 and CD47 at lower doses; (2) MHI-LFX@Pt(IV)@Lip was constructed, in which cisplatin prodrug Pt(IV) and MHI-LFX were co-loaded into clinically available liposomal nanoparticles. MHI-LFX@Pt(IV)@Lip nanoparticles can re-empower fluoroquinolone drugs to overcome platinum-based chemotherapy-immunotherapy tolerance. Attached Figure Description

[0036] Figure 1 Immunoblot analysis of PD-L1 and CD47 proteins in 5637 cells after treatment with different dose gradients of MHI-LFX for 24 h. Figure 2 Western blot comparison analysis of specified proteins in 5637 cells after treatment with solvent control, free MHI, LFX, or MHI-LFX for 24 h; Figure 3 A schematic diagram of the preparation process of MHI-LFX@Pt(IV)@Lip nanoparticles; Figure 4A Representative TEM images and DLS particle size distribution maps of MHI-LFX@Lip show the morphology and particle size distribution of the lipid nanoparticles. Figure 4B Representative TEM images and DLS particle size distribution maps of Pt(IV)@Lip; Figure 4C Representative TEM images and DLS particle size distribution maps of MHI-LFX@Pt(IV)@Lip; Figure 4D The UV-Vis absorption spectra of Blank Lip, MHI-LFX, Pt(IV), and the encapsulated MHI-LFX@Pt(IV)@Lip in aqueous solution are shown. Figure 4E The results show the surface charge (Zeta potential) of the synthesized nanocarriers. Figure 4F To monitor the stability of MHI-LFX@Pt(IV)@Lip within 48 hours in different physiological media; Figure 4G The cumulative release curve of MHI-LFX from the MHI-LFX@Pt(IV)@Lip system in PBS; Figure 4H To investigate the in vivo biodistribution and fluorescence tracking of 4T1 tumor-bearing mice after intravenous injection of MHI-LFX@Pt(IV)@Lip, and to image isolated organs and tumor tissues 24 h after administration; Figure 4I Representative images for evaluating the blood compatibility of different concentrations of MHI-LFX@Alb using a hemolysis assay; Figure 4J A statistical graph showing the blood compatibility of different concentrations of MHI-LFX@Alb assessed using a hemolysis assay; Figure 5A Western blot analysis was performed on the expression of PD-L1 and CD47 proteins in 5637 cells after different treatments. Figure 5B Western blot analysis was performed on the expression of PD-L1 and CD47 proteins in 5637 cells after different treatments. Figure 5C To detect PD-L1 expression in 5637 cells by flow cytometry; Figure 5D To detect CD47 expression in 5637 cells by flow cytometry; Figure 5E Typical images for immunofluorescence detection of PD-L1 and CD47 expression; Figure 5F To detect the expression of specific genes in 5637 cells after treatment with vehicle or MHI-LFX (1 μM) for 24 h by RT-qPCR; Figure 5G Typical images for immunofluorescence detection of γ-H2AX expression; Figure 5H Representative images for flow cytometry analysis of apoptosis induced by different nano-formulations in 5637 cells; Figure 5I Statistical graphs for flow cytometry analysis of apoptosis induced by different nano-formulations in 5637 cells; Figure 5J To evaluate its inhibitory effect on the proliferation of 5637 cells in a clonogenic assay; Figure 5KTo analyze the pro-apoptotic effect of T cells on T24 cells using flow cytometry; Figure 5L To assess the cytotoxicity of T cells against T24 cells; Figure 5M qRT-PCR analysis of IL-2 and IFN-γ mRNA levels after co-culturing T cells with pretreated 5637 cells; Figure 5N To analyze the phagocytic activity of macrophages (F4 / 80 staining) on ​​carboxy-DFFDA SE-labeled 4T1 cells using immunofluorescence; Figure 5O To analyze the phagocytic activity of macrophages (F4 / 80 staining) on ​​carboxy-DFFDA SE-labeled 4T1 cells by flow cytometry; Figure 5P A schematic diagram of the signaling pathways activated by combined MHI-LFX and Pt(IV) therapy; Figure 6A This is a schematic diagram of the experimental design, illustrating the timeline of primary / recurrent (second implantation) tumor inoculation and treatment regimen; Figure 6B The dynamic growth curve and photograph of the primary tumor on day 14; Figure 6C The weight of the primary tumor on day 14; Figure 6D GSEA transcriptomic analysis of 4T1 tumor tissues collected after MHI-LFX@Pt(IV)@Lip treatment; Figure 6E CD3 levels in in situ 4T1 tumors after different treatments + T cells, CD4 + T cells and CD8 + Flow cytometry analysis of T cells; Figure 6F Immunohistochemical (IHC) analysis of PD-L1, CD47 and γH2AX expression levels after different treatments; Figure 6G These are representative images of PD-L1 and CD47 protein expression levels detected by Western blot. Figure 6H A statistical graph showing the expression levels of PD-L1 and CD47 proteins detected by Western blot. Figure 6I Immunohistochemical (IHC) analysis of iNOS, CD86 and γH2AX expression levels after different treatments; Figure 6J Growth curves and tumor images of recurrent 4T1 tumors; Figure 6K The weight of 4T1 tumors collected on day 38; Figure 6L To further challenge CD3 in 4T1 tumors after different treatments + T cells, CD4 + T cells and CD8 + Flow cytometry analysis of T cells; Figure 6M Flow cytometry analysis of T cells in recurrent 4T1 tumors; Figure 6N A graphical summary of a study on lung metastases; Figure 6O The results include representative gross lung photographs (fixed in Bouin solution), whole-section H&E stained images, and statistical quantitative analysis of metastatic lesions.

[0037] In the above figure, G1 is physiological saline (Vehicle), G2 is MHI-LFX@Lip, G3 is Pt(IV)@Lip, and G4 is MHI-LFX@Pt(IV)@Lip.

[0038] In the above figure, **p < 0.01, ***p < 0.001. Detailed Implementation

[0039] The technical problems to be solved, the technical solutions, and the beneficial effects of the present invention will be described in detail below with reference to specific embodiments. The following embodiments will help those skilled in the art to further understand the present invention, but do not limit the present invention in any way. It should be noted that those skilled in the art can make several modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention.

[0040] All raw materials used in the specific implementation method can be commercially available or prepared using conventional methods. In the example, the experimental cells used are commercially available 5637 cells.

[0041] Example 1

[0042] (1) First, synthesize heptamethrin dye (MHI): Sodium acetate (975 mg, 11.9 mmol), N-[(3-(anilinemethylene)-2-chloro-1-cyclohexene-1-methylene]aniline monohydrochloride (4.7 g, 13.0 mmol), n-ethyl-2,3,3-trimethylindole iodide (4.05 g, 11.8 mmol), and 1-(5-carboxyl)-2,3,3-trimethylindole bromide (3.88 g, 11.8 mmol) were added to 150 mL of anhydrous ethanol at room temperature. The reaction mixture was then refluxed at 75 °C in an oil bath. After 3 h, the reaction mixture was evaporated to dryness using a rotary evaporator, and MHI was purified by silica gel column chromatography.

[0043] (2) Further chemical synthesis of heptamethrin-based levofloxacin derivatives; (2.1) Synthesis of LFX-NH2: Levofloxacin (1.81 g, 5.0 mmol) was dissolved in a mixed organic solution of 60 mL anhydrous dichloroethane and 60 mL methanol. Excess N-Boc-propanediamine (8 mmol) was added, along with 5.0 mmol of catalyst 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (DMTMM). The reaction was carried out at room temperature for 24 hours. The reaction system was evaporated to dryness using a rotary evaporator, and LFX-NH2 was purified by silica gel column chromatography. 2- Boc. Then, Boc is removed via trifluoroacetic acid, and NaOH desaltes to form LFX-NH2; (2.2) Synthesis of heptamethrin-based levofloxacin derivatives: LFX-NH2 (1.61 g, 4 mmol) was dissolved in a mixed organic solution of 60 mL anhydrous dichloroethane and 60 mL methanol. MHI (1.44 g, 2 mmol) and 2.0 mmol of catalyst DMTMM were added, and the reaction was carried out at room temperature for 24 hours. Subsequently, the solvents dichloromethane and methanol were removed under reduced pressure. The reaction system was evaporated to dryness using a rotary evaporator, and the final product, heptamethrin-based levofloxacin derivative MHI-LFX (1.56 g, purity 95.8%), was purified by silica gel column chromatography.

[0044] Example 2

[0045] (1) First, synthesize heptamethrin dye (MHI): At room temperature, sodium acetate (10 mmol), N-[(3-(anilinemethylene)-2-chloro-1-cyclohexene-1-methylene]aniline monohydrochloride (12 mmol), n-ethyl-2,3,3-trimethylindole iodide (8 mmol), and 1-(5-carboxyl)-2,3,3-trimethylindole bromide (10 mmol) were added to 150 mL of anhydrous ethanol. The reaction mixture was then refluxed at 75 °C in an oil bath. After 3 h, the reaction mixture was evaporated to dryness using a rotary evaporator, and MHI was purified by silica gel column chromatography.

[0046] (2) Further chemical synthesis of heptamethrin-based levofloxacin derivatives; (2.1) Synthesis of LFX-NH2: Levofloxacin (5.0 mmol) was dissolved in a mixed organic solution of 60 mL anhydrous dichloroethane and 60 mL methanol. Excess N-Boc-propanediamine (10 mmol) was added, along with 4.0 mmol of catalyst 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (DMTMM). The reaction was carried out at room temperature for 24 hours. The reaction system was dried by rotary evaporation and LFX-NH2 was purified by silica gel column chromatography. 2- Boc. Then, Boc is removed via trifluoroacetic acid, and NaOH desaltes to form LFX-NH2; (2.2) Synthesis of heptamethrin-based levofloxacin derivatives: LFX-NH2 (1.61 g, 4 mmol) was dissolved in a mixed organic solution of 60 mL anhydrous dichloroethane and 60 mL methanol. MHI (4 mmol) and 4.0 mmol of DMTMM catalyst were added, and the reaction was carried out at room temperature for 24 hours. Subsequently, the solvents dichloromethane and methanol were removed under reduced pressure. The reaction system was evaporated to dryness using a rotary evaporator, and the final product, heptamethrin-based levofloxacin derivative MHI-LFX, was purified by silica gel column chromatography.

[0047] Example 3

[0048] (1) First, synthesize heptamethrin dye (MHI): Sodium acetate (10 mmol), N-[(3-(anilinemethylene)-2-chloro-1-cyclohexene-1-methylene]aniline monohydrochloride (9 mmol), n-ethyl-2,3,3-trimethylindole iodide (10 mmol), and 1-(5-carboxyl)-2,3,3-trimethylindole bromide (11 mmol) were added to 150 mL of anhydrous ethanol at room temperature. The reaction mixture was then refluxed at 75 °C in an oil bath. After 3 h, the reaction mixture was evaporated to dryness using a rotary evaporator, and MHI was purified by silica gel column chromatography.

[0049] (2) Further chemical synthesis of heptamethrin-based levofloxacin derivatives; (2.1) Synthesis of LFX-NH2: Levofloxacin (1.81 g, 5.0 mmol) was dissolved in a mixed organic solution of 60 mL anhydrous dichloroethane and 60 mL methanol. Excess N-Boc-propanediamine (9 mmol) was added, along with 6.0 mmol of catalyst 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride (DMTMM). The reaction was carried out at room temperature for 24 hours. The reaction system was evaporated to dryness using a rotary evaporator, and LFX-NH2 was purified by silica gel column chromatography. 2- Boc. Then, Boc is removed via trifluoroacetic acid, and NaOH desaltes to form LFX-NH2; (2.2) Synthesis of heptamethrin-based levofloxacin derivatives: LFX-NH2 (1.61 g, 4 mmol) was dissolved in a mixed organic solution of 60 mL anhydrous dichloroethane and 60 mL methanol. MHI (1 mmol) and 1.0 mmol of catalyst DMTMM were added, and the reaction was carried out at room temperature for 24 hours. Subsequently, the solvents dichloromethane and methanol were removed under reduced pressure. The reaction system was evaporated to dryness using a rotary evaporator, and the final product, heptamethrin-based levofloxacin derivative MHI-LFX, was purified by silica gel column chromatography.

[0050] Western blot functional experiments showed that even at low concentrations, the heptamethrin derivative levofloxacin MHI-LFX effectively induced AMPK phosphorylation and simultaneously downregulated the expression of PD-L1 and CD47. Figure 1 As shown, in contrast, the same low doses of either MHI or LFX failed to induce similar immune checkpoint inhibition, such as Figure 2 As shown. These results demonstrate that the MHI group in Examples 1-3 successfully targeted and delivered LFX to the mitochondria, thereby enhancing its pharmacological activity.

[0051] Application Example 1 (1.1) Weigh Pt(II) (596 mg, 2 mmol), then add excess 30% hydrogen peroxide solution, react under light-protected conditions for 8 h, centrifuge, filter, extract and purify to obtain Pt(IV)-OH. Weigh Pt(IV)-OH (665 mg, 2 mmol), add 30 mL DMSO solution, stir at room temperature until completely dissolved. Then add 4 mmol succinic anhydride, react at room temperature for 24 h. After the reaction is complete, remove the reaction solution by vacuum rotary evaporation, then add 10 mL methanol, add a certain amount of diethyl ether to precipitate the product, and repeatedly purify to obtain Pt(IV)-COOH.

[0052] (1.2) Weigh Pt(IV)-COOH (267 mg, 0.5 mmol), add 10 mL DMSO, then add 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC, 116 mg, 0.75 mmol), and then add N-hydroxysuccinimide (NHS, 86 mg, 0.75 mmol). The reaction solution was reacted at room temperature in the dark for 24 h. Then, DSPE-NH2 (561 mg, 0.75 mmol) was added to the reaction solution, and the reaction was continued for 48 h. After the reaction was completed, the catalysts EDC and NHS were removed by two-phase extraction of the organic and aqueous phases, and the product Pt(IV) was further precipitated.

[0053] (2) A mixture of HSPC (35 mg), cholesterol (15 mg), DSPE-PEG2000 (5 mg), and Pt(IV) (25 mg) was thoroughly dissolved in chloroform. The solution was placed in a round-bottom flask and treated with a rotary evaporator at 45 °C for 20 minutes to form a dry lipid film. 10 mL of distilled water and 2.5 mg of MHI-LFX prepared in Example 1 were added to the film, followed by sonication for 5 minutes to obtain a liposome emulsion. The resulting vesicles were manually extruded 11 times through a 200 nm polycarbonate membrane for homogenization. To remove unencapsulated drug, the solution was subjected to pressure ultrafiltration in an Amicon® stirred ultrafiltration cup (molecular weight cutoff of 30 kDa) until a colorless filtrate was obtained. The final prepared MHI-LFX@Pt(IV)@Lip (approximately 5 mL) was stored at 4 °C.

[0054] This invention uses liposomes as a delivery platform, such as Figure 3 As shown. To improve the safety of MHI-LFX and prolong its accumulation time at the tumor site, MHI-LFX@Lip was first prepared. To achieve the synergistic therapeutic effect between MHI-LFX and Pt(IV), this invention utilizes the hydrophilicity of MHI-LFX and the hydrophobicity of Pt(IV) to construct a dual-drug loaded nanosystem of MHI-LFX@Pt(IV)@Lip.

[0055] Comparative Example 1 Blank liposomes (Blank Lip), MHI-LFX@Lip, and Pt(IV)@Lip were prepared using the same procedures as in Example 1 and Application Example 1, with the same drug loading.

[0056] Preparation of blank liposomes: A mixture of HSPC (35 mg), cholesterol (15 mg), and DSPE-PEG2000 (5 mg) was thoroughly dissolved in chloroform. The solution was placed in a round-bottom flask and treated with a rotary evaporator at 45 °C for 20 minutes to form a dry lipid film. 10 mL of distilled water was added to the film, followed by sonication for 5 minutes to obtain a liposome emulsion. The resulting vesicles were manually extruded 11 times through a 200 nm polycarbonate membrane for homogenization. To remove unencapsulated drug, the solution was subjected to pressure ultrafiltration in an Amicon® stirred ultrafiltration cup (molecular weight cutoff of 30 kDa) until a colorless filtrate was obtained. The final prepared blank liposomes were stored at 4 °C.

[0057] Preparation of MHI-LFX@Lip: A mixture of HSPC (35 mg), cholesterol (15 mg), and DSPE-PEG2000 (5 mg) was thoroughly dissolved in chloroform. The solution was placed in a round-bottom flask and treated with a rotary evaporator at 45 °C for 20 minutes to form a dried lipid film. 10 mL of distilled water and 2.5 mg of MHI-LFX were added to the film, followed by sonication for 5 minutes to obtain a liposome emulsion. The resulting vesicles were manually extruded 11 times through a 200 nm polycarbonate membrane for homogenization. To remove unencapsulated drug, the solution was subjected to pressure ultrafiltration in an Amicon® stirred ultrafiltration cup (molecular weight cutoff of 30 kDa) until a colorless filtrate was obtained. The final prepared MHI-LFX@Lip (approximately 5 mL) was stored at 4 °C.

[0058] Preparation of Pt(IV)@Lip: A mixture of HSPC (35 mg), cholesterol (15 mg), DSPE-PEG2000 (5 mg), and Pt(IV) (25 mg) was thoroughly dissolved in chloroform. The solution was placed in a round-bottom flask and treated with a rotary evaporator at 45°C for 20 minutes to form a dried lipid film. 10 mL of distilled water was added to the film, followed by sonication for 5 minutes to obtain a liposome emulsion. The resulting vesicles were manually extruded 11 times through a 200 nm polycarbonate membrane for homogenization. To remove unencapsulated drug, the solution was subjected to pressure ultrafiltration in an Amicon® stirred ultrafiltration cup (molecular weight cutoff of 30 kDa) until a colorless filtrate was obtained. The final prepared Pt(IV)@Lip (approximately 5 mL) was stored at 4°C.

[0059] Test Example 1: Preparation and Characterization of MHI-LFX@Pt(IV)@Lip Transmission electron microscopy (TEM) imaging results showed that MHI-LFX@Lip, Pt(IV)@Lip, and MHI-LFX@Pt(IV)@Lip all exhibited a uniform spherical morphology and had similar hydrated particle sizes of 182.3 ± 3.2, 182.9 ± 3.8, and 186.6 ± 5.3 nm, respectively. Figures 4A-4C As shown. The characteristic UV-Vis absorption peak at approximately 780 nm confirmed the high efficiency of MHI-LFX loading, with an encapsulation efficiency of 85.1 ± 1.8%. Figure 4D As shown. These nanoformulations exhibit stable Zeta potentials ranging from -27.5 to -28.37 mV, as... Figure 4E As shown.

[0060] Stability experiments showed that after incubation for 48 h in different physiological media (PBS or 10% FBS) and at different temperatures (25°C or 37°C), the particle size remained stable. Figure 4F As shown. Furthermore, MHI-LFX@Pt(IV)@Lip exhibits a sustained release characteristic of MHI-LFX, as... Figure 4G As shown.

[0061] In vivo fluorescence imaging further confirmed that these nanoparticles can preferentially accumulate at tumor sites, such as... Figure 4H As shown, it exhibits negligible hemolytic activity, such as Figure 4I-4J As shown.

[0062] Test Example 2: MHI-LFX disrupts platinum-induced DNA damage repair and tumor cell immune escape. Both cisplatin (Cis-Pt) and Pt(IV) induced dose-dependent upregulation of PD-L1 and CD47 in 5637 cells, such as Figure 5A As shown, this effect can be effectively reversed by MHI-LFX, as verified by Western blot, flow cytometry, and immunofluorescence experiments. Figure 5B-5E As shown, considering that PD-L1 in the cytoplasm can stabilize the mRNA of key DNA damage response (DDR) factors, including NBS1, RAD50, and MRE11, further investigation is needed to determine whether MHI-LFX can disrupt this defense mechanism. Figure 5F-5G As shown in the figure. The results showed that in Pt(IV)-stimulated 5637 cells, MHI-LFX significantly inhibited the accumulation of intracellular PD-L1, while reducing the mRNA transcription levels of NBS1, MRE11, and RAD50, as shown in the figure. Figure 5F-5G As shown. This intervention further exacerbated DNA double-strand breaks, manifested as a significant increase in γ-H2AX, as... Figure 5G As shown.

[0063] Therefore, MHI-LFX@Pt(IV)@Lip is significantly superior to single therapy in inducing apoptosis and inhibiting cell invasion, such as... Figure 5H-5J As shown in the figure. These results indicate that MHI-LFX enhances the sensitivity of tumor cells to Pt(IV) by weakening intracellular PD-L1-driven DNA repair mechanisms.

[0064] PD-L1 expression promotes tumor cells' evasion of T cell-mediated cytotoxicity and immune surveillance. To evaluate the effect of MHI-LFX on T cell-mediated cytotoxicity, in vitro experiments were conducted by pretreating 5637 cells with MHI-LFX before co-culturing them with T cells. Figure 5K-5M As shown. The results showed that the downregulation of T cell IL-2 and IFN-γ mRNA induced by 5637 cells could be significantly restored by MHI-LFX, such as Figure 5M As shown. Furthermore, MHI-LFX can synergistically work with T cells to significantly inhibit the proliferation of 5637 cells and induce apoptosis, with efficacy significantly superior to T cells or MHI-LFX alone, such as... Figure 5K-5L As shown. T24 cells were pretreated with vehicle (physiological saline) or MHI-LFX@Lip before being co-cultured with T cells. T cell-induced apoptosis was analyzed by crystal violet staining and flow cytometry. CD47 expression allows tumor cells to evade immune clearance via a "don't eat me" signal. Immunofluorescence and flow cytometry analysis confirmed that MHI-LFX significantly promoted the phagocytosis of T24 cells by bone marrow-derived macrophages (BMDMs). Figure 5M-5O As shown.

[0065] In summary, these results indicate that MHI-LFX can enhance T cell activation and promote macrophage phagocytosis, such as Figure 5P As shown.

[0066] Test Case 3: MHI-LFX@Pt(IV)@Lip inhibits in situ tumor growth and prevents postoperative tumor recurrence.

[0067] The in vivo therapeutic efficacy of MHI-LFX@Pt(IV)@Lip was further evaluated in use case 1, such as... Figure 6A As shown. It is noteworthy that MHI-LFX@Pt(IV)@Lip treatment achieved almost complete tumor eradication and completely halted tumor growth, demonstrating significantly superior synergistic efficacy compared to MHI-LFX@Lip and Pt(IV)@Lip monotherapy, such as... Figures 6A-6C As shown.

[0068] To elucidate its potential mechanism, transcriptome analysis was performed on tumor tissue 48 hours after intravenous administration, such as... Figure 6DAs shown, consistent with in vitro experimental results, GSEA analysis confirmed that MHI-LFX@Pt(IV)@Lip can significantly inhibit mitochondrial respiratory function-related mechanisms.

[0069] Flow cytometry, immunohistochemistry, and Western blot analysis of tumor tissues showed that Pt(IV)@Lip-induced immunogenic cell death (ICD) could induce a certain degree of T cell and macrophage recruitment, such as... Figure 6E-6I As shown.

[0070] However, this immune response is subsequently limited by compensatory upregulation of PD-L1 and CD47 on the surface of tumor cells, thereby weakening the effector function of infiltrating leukocytes, such as Figure 6G-6I As shown, in contrast, MHI-LFX@Lip can effectively inhibit the expression of PD-L1 and CD47.

[0071] Although MHI-LFX@Lip monotherapy can moderately enhance T cell infiltration, its synergistic combination with Pt(IV) can significantly enhance the recruitment of T cells and macrophages. Figure 6F-6J As shown. This combined effect is significantly superior to MHI-LFX@Lip or Pt(IV)@Lip monotherapy, indicating its strong immunosensitizing ability, such as Figure 6F-6J As shown. Furthermore, MHI-LFX-mediated intracellular PD-L1 regulation further exacerbates Pt(IV)-induced DNA damage, such as... Figure 6F As shown.

[0072] Given the potent synergistic immunomodulatory effects of MHI-LFX and Pt(IV), this combination therapy was expected to significantly enhance the immune memory effect. Results showed that while MHI-LFX@Lip or Pt(IV)@Lip, as initial treatment, numerically reduced tumor volume compared to the control group, the difference was not statistically significant. In stark contrast, MHI-LFX@Pt(IV)@Lip significantly inhibited the growth of recurrent tumors, such as... Figure 6J-6K As shown.

[0073] To verify whether this antitumor resistance is mediated by an immune mechanism, this study further analyzed T cell infiltration in secondary tumors. The results showed that Pt(IV)@Lip had almost no significant effect, MHI-LFX@Lip induced only a slight increase, while MHI-LFX@Pt(IV)@Lip treatment significantly promoted T cell infiltration and enrichment. Figure 6L As shown. Most notably, MHI-LFX@Pt(IV)@Lip completely eliminated lung metastases, as... Figure 6M-6O As shown.

[0074] These results indicate that the combination therapy of MHI-LFX@Pt(IV)@Lip can effectively overcome the immunosuppressive barriers that usually lead to tumor recurrence and metastasis.

Claims

1. A heptamethrin-based levofloxacin derivative, characterized in that, The structural schematic diagram of the heptamethrin-based levofloxacin derivative is shown in (I). (I)。 2. A method for preparing a heptamethrin-based levofloxacin derivative as described in claim 1, characterized in that, The preparation method comprises the following steps: (1) First, synthesize heptamethrin dye: At room temperature, first add sodium acetate, N-[(3-(anilinemethylene)-2-chloro-1-cyclohexene-1-methylene]aniline monohydrochloride, n-ethyl-2,3,3-trimethylindole iodide and 1-(5-carboxyl)-2,3,3-trimethylindole bromide to anhydrous ethanol, then mix the above reactants in an oil bath and heat under reflux to obtain heptamethrin dye; (2) Re-chemical synthesis of heptamethrin-based levofloxacin derivatives (2.1) Synthesis of LFX-NH2: Levofloxacin was dissolved in a mixed organic solution of anhydrous dichloroethane and methanol, N-Boc-propanediamine was added, a catalyst was added, and the mixture was reacted at room temperature and then purified to obtain LFX-NH2. 2- Boc, after purification, is converted into LFX-NH2 by trifluoroacetic acid and NaOH; (2.2) Synthesis of heptamethrin-based levofloxacin derivatives: LFX-NH2 was dissolved in a mixed organic solution of anhydrous dichloroethane and methanol, MHI and catalyst DMTMM were added, and the reaction was carried out at room temperature. After removing the organic solvent, the product heptamethrin-based levofloxacin derivatives were obtained by purification.

3. The method for preparing heptamethrin-based levofloxacin derivatives according to claim 2, characterized in that, In step (1), the molar ratio of sodium acetate, N-[(3-(anilinemethylene)-2-chloro-1-cyclohexene-1-methylene]aniline monohydrochloride, n-ethyl-2,3,3-trimethylindole iodide, and 1-(5-carboxyl)-2,3,3-trimethylindole bromide is 1:0.8-1.2:0.8-1.2:0.8-1.

2.

4. The method for preparing heptamethrin-based levofloxacin derivatives according to claim 2, characterized in that, In step (2), the molar ratio of N-Boc-propanediamine, catalyst and levofloxacin is 1.5-2:0.8-1.2:1, and the molar ratio of MHI, catalyst and LFX-NH2 is 0.1-1:0.1-1:

1. The catalyst is selected from 4-(4,6-dimethoxytriazine-2-yl)-4-methylmorpholine hydrochloride.

5. The method of preparing septamethine indocyanine-based levofloxacin derivative according to claim 2, characterized in that, In a mixed organic solution of anhydrous dichloroethane and methanol, the volume ratio of anhydrous dichloroethane to methanol is 1:0.5-1.

5.

6. The application of a heptamethrin-based levofloxacin derivative as described in claim 1 in the construction of MHI-LFX@Pt(IV)@Lip nanoparticles, characterized in that, The nanostructure of MHI-LFX@Pt(IV)@Lip is shown in (II): (I) and (II).

7. The application of the heptamethrin-based levofloxacin derivative according to claim 6, characterized in that, The preparation method of the MHI-LFX@Pt(IV)@Lip nanoparticles includes the following steps: (1) Synthesis of Pt(IV) tetravalent platinum prodrug (1.1) Weigh Pt(II), add excess hydrogen peroxide solution, react under light-protected conditions, centrifuge, filter, extract and purify to obtain Pt(IV)-OH; then add DMSO solution, stir and dissolve at room temperature, add succinic anhydride, after the reaction at room temperature is completed, remove the reaction solution, add methanol and diethyl ether in sequence, and purify repeatedly to obtain Pt(IV)-COOH; (1.2) Weigh Pt(IV)-COOH, add DMSO solution, and then add catalysts 1-ethyl-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide in sequence. After the reaction solution is protected from light at room temperature, add DSPE-NH2 to the reaction solution and continue the reaction. After the reaction is completed, remove the catalyst and further precipitate to obtain the product Pt(IV) tetravalent platinum prodrug. (2) Construction of MHI-LFX@Pt(IV)@Lip nanoparticles A mixture of HSPC, cholesterol, DSPE-PEG2000, and Pt(IV) was dissolved in chloroform to form a lipid film. Distilled water and MHI-LFX were then added to the film, and the mixture was sonicated to obtain a liposome emulsion. The resulting vesicles were homogenized. Finally, the solution was subjected to pressure ultrafiltration until a colorless filtrate was obtained, which was MHI-LFX@Pt(IV)@Lip nanoparticles.

8. The application of the heptamethrin-based levofloxacin derivatives according to claim 7, characterized in that: In step (1), the molar ratio of succinic anhydride to Pt(IV)-OH is 1.5-2.5:1, and the molar ratio of Pt(IV)-COOH, catalyst 1-ethyl-(3-dimethylaminopropyl)carbodiimide, N-hydroxysuccinimide, and DSPE-NH2 is 1:1-2:1-2:1-2.

9. Use of a heptamethine cyanine derivative of levofloxacin according to claim 7 or 8, characterized in that: The steps for constructing MHI-LFX@Pt(IV)@Lip nanoparticles in step (2) are as follows: the mass ratio of HSPC, cholesterol, DSPE-PEG2000, and Pt(IV) is 1-2:0.5-1.5:1-2:1, and the amount of distilled water, MHI-LFX, and Pt(IV) used is 0.2-0.6 mL:0.05-0.2 mg:1 mg.

10. The use of the heptamethine cyanine derivative of levofloxacin according to claim 6 or 7, characterized in that: The MHI-LFX@Pt(IV)@Lip nanoparticles serve as a liposome-loaded nano-drug delivery system.